RC28
Ophthalmic diseases (e.g., wAMD, DME)
Phase 2/3Licensed to Santen
Key Facts
About RemeGen
A leading Chinese biotech developing and commercializing innovative biologics and ADCs for autoimmune diseases, oncology, and ophthalmology.
View full company profile